Oncoinvent ASA: Notification of trade - primary insider/close associate

08 Dec 2025 06:55 CET

8 December 2025: Reference is made to the stock exchange announcements published
by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025, and
subsequent announcements, regarding the fully underwritten rights issue of
260,000,000 new shares in the Company (the "Offer Shares") raising gross
proceeds of NOK 130 million (the "Rights Issue"). Further, reference is made to
the stock exchange announcement published by the Company on 5 December 2025
regarding the resolution by the board of directors of the Company to issue
31,199,997 new shares in the Company, each with a nominal value of NOK 0.50, at
a subscription price of NOK 0.50 per share (the "Underwriting Commission
Shares") to be delivered to the underwriters pursuant to the subscription and
underwriting agreements dated 30 June 2025 as settlement of their entitlement to
an underwriting fee under said agreements.

Please see the attached notifications of trade for information regarding the
allocation and subscription of Underwriting Commission Shares by certain primary
insiders and their close associates.

***

This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and Section 5-12 of the Norwegian
Securities Trading Act.

For further information, please contact:

Oystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical
development program in two indications. One Phase 1 trial and one Phase 1/2a
trial have been completed and one randomized Phase 2 trial is currently ongoing
in the US, UK and Europe. Early clinical efficacy data are highly encouraging,
and no serious toxicity or safety concerns have been reported to date. The
Oncoinvent team consists of approx. 40 employees and runs a state-of-the-art
manufacturing facility to produce drug products for clinical trials in Nydalen,
Oslo. Oncoinvent is listed on the Oslo Stock Exchange.

About Radspherin

Radspherin® is an investigational radiopharmaceutical designed for the local
treatment of cancer that has spread to body cavities. It consists of calcium
carbonate microparticles containing the radioactive material radium-224. The
mode of action is the decay of radium-224 emitting alpha-particles, a highly
potent form of ionizing radiation. Radspherin® is investigated in clinical
studies to treat peritoneal carcinomatoses from ovarian and colorectal cancer
and it is administered intraperitoneally after surgical resection with removal
of all macroscopic tumors.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These forward
-looking statements represent Oncoinvent's expectations as of the date of this
press release, and Oncoinvent disclaims any obligation to update the forward
-looking statements. These forward-looking statements are subject to known and
unknown risks and uncertainties that may cause actual results to differ
materially, including with respect to whether the results of clinical or other
studies will support the use of our product offerings, the impact of results of
such studies, our expectations of the reliability, accuracy and performance of
our tests, or of the benefits of our tests and product offerings to patients,
providers and payers.

More information:
Access the news on Oslo Bors NewsWeb site

661415_2025_12_05_PDMR_Attachment_subscription_and_allocation_of_UWC_shares.pdf